The current recommendations, produced by the Turkish Association for the Study of the Liver, Acute Liver Failure and Liver Transplantation Special Interest Group, suggest a reduced need for hepatitis B immunoglobulin administration with effective long-term suppression of hepatitis B virus replication using potent nucleos(t) ide analogs after liver transplantation
📌 3 Key Takeaways
🎯
Objective & Hypothesis:The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplantation is considered as the standard of care for prophylaxis against hepatitis B virus recurrence.
📊
Key Findings & Data:However, the recommended doses, route of administration, and duration of HBIG administration remain unclear.
💡
Conclusion & Impact:The current recommendations, produced by the Turkish Association for the Study of the Liver, Acute Liver Failure and Liver Transplantation Special Interest Group, suggest a reduced need for hepatitis B immunoglobulin administration with effective long-term suppression of hepatitis B virus replication using potent nucleos(t) ide analogs after liver transplantation
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplantation is considered as the standard of care for prophylaxis against hepatitis B virus recurrence. However, the recommended doses, route of administration, and duration of HBIG administration remain unclear. Moreover, hepatitis B immunoglobulin-free prophylaxis with potent nucleos(t)ide analogs has shown promising disease outcomes in preventing hepatitis B virus recurrence. The current recommendations, produced by the Turkish Association for the Study of the Liver, Acute Liver Failure and Liver Transplantation Special Interest Group, suggest a reduced need for hepatitis B immunoglobulin administration with effective long-term suppression of hepatitis B virus replication using potent nucleos(t) ide analogs after liver transplantation
🔖
Cite This Article
AKARSU, M., ONEM, S., TURAN, İ., ADALI, G., KAYHAN, M. A., AKYILDIZ, M., ALADAĞ, M., BALABAN, Y. H., DANIŞ, N., DAYANGAÇ, M., GENÇDAL, G., SÜMER, H., SERTESEN, E., GÜRAKAR, M., HARPUTLUOĞLU, M. M., KABAÇAM, G., KARADEMİR, S., KIYICI, M., İDİLMAN, R., karasu, Z. (2021). Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. Turkish Journal of Gastroenterology, Cilt: 32 - Sayı: 9, 712–719. https://ajindex.com/articles/408882
European Association for the Study of the Liver (EASL). EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017
67(2):370-398. [CrossRef] 2. Tozun N, Ozdogan O, Cakaloglu Y, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015
21(11):1020-1026. [CrossRef] 3. Te H, Doucette K. Viral hepatitis: guidelines by the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant. 2019
33(9):e13514. [CrossRef] 4. Orfanidou A, Papatheodoridis GV, Cholongitas E. Antiviral prophylaxis against hepatitis B recurrence after liver transplantation: current concepts. Liver Int. 2021
41(7):1448-1461. [CrossRef] 5. Schilling R, Ijaz S, Davidoff M, et al. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol. 2003
77(16):8882-8892. [CrossRef] 6. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology. 2000
32(6):1189-1195. [CrossRef] 7. United States Preventive Services Task Force. Grade Definitions. Available at: https://ww w.usp reven tives ervic estas kforc e.org /apps / grad edef. jsp#a fter2 012. 8. Phillips MJ, Cameron R, Flowers MA, et al. Post-transplant recurrent hepatitis B viral liver disease: viral-burden, steatoviral, and fibroviral hepatitis B. Am J Pathol. 1992
140(6):1295-1308. 9. Mcgory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation. 1996
61(9):1358- 1364. [CrossRef] 10. Marzano A, Gaia S, Ghisetti V, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl. 2005
11(4):402-409. [CrossRef] 11. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993
329(25):1842-1847. [CrossRef] 12. Verna EC. Updated hepatitis B Guidance: implications for liver transplant patients. Liver Transpl. 2018
24(4):465-469. [CrossRef] 13. Chauhan R, Lingala S, Gadiparthi C, et al. Reactivation of hepatitis B after liver transplantation: current knowledge, molecular mechanisms and implications in management. World J Hepatol. 2018